A detailed history of Shah Capital Management transactions in Novavax Inc stock. As of the latest transaction made, Shah Capital Management holds 9,815,541 shares of NVAX stock, worth $101 Million. This represents 40.63% of its overall portfolio holdings.

Number of Shares
9,815,541
Previous 9,662,090 1.59%
Holding current value
$101 Million
Previous $122 Million 1.35%
% of portfolio
40.63%
Previous 41.87%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

BUY
$10.71 - $17.11 $1.64 Million - $2.63 Million
153,451 Added 1.59%
9,815,541 $124 Million
Q2 2024

Aug 12, 2024

BUY
$3.89 - $20.97 $6.01 Million - $32.4 Million
1,544,263 Added 19.02%
9,662,090 $122 Million
Q1 2024

May 15, 2024

BUY
$3.76 - $6.02 $1.27 Million - $2.03 Million
337,071 Added 4.33%
8,117,827 $38.8 Million
Q4 2023

Feb 05, 2024

BUY
$4.8 - $7.67 $6.96 Million - $11.1 Million
1,450,000 Added 22.9%
7,780,756 $37.3 Million
Q3 2023

Oct 11, 2023

BUY
$6.81 - $9.74 $5.79 Million - $8.28 Million
850,000 Added 15.51%
6,330,756 $45.8 Million
Q2 2023

Jul 13, 2023

BUY
$6.67 - $9.52 $8.2 Million - $11.7 Million
1,229,680 Added 28.93%
5,480,756 $40.7 Million
Q2 2023

Jul 12, 2023

SELL
$6.67 - $9.52 $8.2 Million - $11.7 Million
-1,229,680 Reduced 22.44%
4,251,076 $31.6 Million
Q2 2023

Jul 12, 2023

BUY
$6.67 - $9.52 $8.2 Million - $11.7 Million
1,229,680 Added 28.93%
5,480,756 $40.7 Million
Q1 2023

May 08, 2023

BUY
$5.76 - $12.48 $20.4 Million - $44.1 Million
3,536,076 Added 494.56%
4,251,076 $29.5 Million
Q4 2022

Jan 13, 2023

BUY
$8.86 - $25.04 $6.33 Million - $17.9 Million
715,000 New
715,000 $7.35 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $802M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Shah Capital Management Portfolio

Follow Shah Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shah Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Shah Capital Management with notifications on news.